Fenwick represented Vida Health, a provider of virtual cardiometabolic care services, in its $28.5 million financing. The round was led by existing investors, including General Atlantic, Ally Bridge, Canvas Ventures, Hercules Capital and other insiders.
Vida will use the funds to further scale and pursue ongoing growth opportunities, particularly in the rapidly expanding obesity and diabetes market. The investment also supports Vida’s mission to improve access to effective, affordable and sustainable cardiometabolic care treatments. More information can be obtained from the company’s announcement.
The Fenwick transaction team was led by corporate partners Michael Esquivel and Ryan Slunaker and included associates Tracy Kennberg, John Clancy and Cecilia Grimaldi.